Pasithea Therapeutics Updates Conference Presentation Timing
ByAinvest
Friday, Aug 29, 2025 8:40 am ET1min read
KTTA--
CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for via the event's website.
Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565) [1][2].
The conference, taking place September 8-10, 2025, in New York City, provides an opportunity for investors and financial professionals to learn more about the company's progress and future plans. The rescheduling of the presentation allows for more engagement with attendees and potential investors.
References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html
[2] https://www.biospace.com/press-releases/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Pasithea Therapeutics Corp has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference to Monday, September 8, at 5:00 PM Eastern Time. CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for. The company is currently testing its lead drug candidate, PAS-004, in a Phase 1 clinical trial in advanced cancer patients and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation, originally scheduled for September 10, 2025, at 2:30 PM ET, has been rescheduled to Monday, September 8, 2025, at 5:00 PM Eastern Time [1][2].CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for via the event's website.
Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565) [1][2].
The conference, taking place September 8-10, 2025, in New York City, provides an opportunity for investors and financial professionals to learn more about the company's progress and future plans. The rescheduling of the presentation allows for more engagement with attendees and potential investors.
References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html
[2] https://www.biospace.com/press-releases/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet